drugset
drugset / Trial / NCT05373277

KF2019#1-trial: Effects of a Thrombocyte Inhibitor on a Cholesterol-lowering Drug

NCT05373277 ↗

Phase 1 Unknown 10 enrolled Helsinki University Central Hospital University of Helsinki · collab
RandomizedCrossoverDouble-blindBasic science

Summary

The cholesterol-lowering drug rosuvastatin is a substrate of the breast cancer resistance protein (BCRP). BCRP is an efflux transporter expressed e.g. in the small intestine. It limits the oral bioavailability of rosuvastatin by transporting rosuvastatin from enterocytes back to the gut lumen. Inhibition of BCRP can increase rosuvastatin bioavailability and systemic concentrations. Ticagrelor is a platelet aggregation inhibitor used in treatment and prevention of atherothrombotic events. Ticagrelor may inhibit BCRP in humans. This study is aimed to investigate the possible interaction of rosuvastatin with ticagrelor. Ten healthy male or female non-smoking volunteers aged 18-40 years are taken into the study. Primary endpoint is area under the plasma concentration-time curve of rosuvastatin.

Timeline

Start
2022-05-11
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosuvastatin Small molecule 10 mg Oral
Comparator Ticagrelor Small molecule 90 mg Oral

Indications

No indication recorded.